AC
MRNS

Aristides Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Aristides Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,453
Closed -$177K – 261
2019
Q4 		$177K Buy
+20,453
New +$115K 0.14% 181

Other funds holding MRNS

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Aristides Capital's MRNS Position: Q1 2020 in Review

Aristides Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2020, closing a stake of 20,453 shares — an estimated $177K sold.

Aristides Capital first reported a position in MRNS in Q4 2019 and held it in 1 quarter. The position peaked at $177K in Q4 2019. 74 funds tracked by Wall St. Rank hold MRNS as of Q1 2020.

  • Aristides Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2020 after selling out during the quarter.
  • Aristides Capital sold 20,453 Marinus Pharmaceuticals, Inc shares in Q1 2020, an estimated $177K.
  • Aristides Capital first reported a position in Marinus Pharmaceuticals, Inc in Q4 2019 and held it in 1 quarter.
  • Aristides Capital's Marinus Pharmaceuticals, Inc position peaked at $177K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.